Literature DB >> 12447864

Evolution of autoimmune hepatitis to primary sclerosing cholangitis: A sequential syndrome.

Ayman A Abdo1, Vincent G Bain, Krikor Kichian, Samuel S Lee.   

Abstract

Recently, the autoimmune hepatitis (AIH)/primary sclerosing cholangitis (PSC) overlap syndrome has been reported increasingly. In this syndrome, patients present with features of both AIH and PSC. It has been suggested that the 2 diseases may be sequential in their occurrence, whereby patients have features of AIH and then after a number of years develop features of PSC, but clear confirmation of evolution has not been documented in adults. We describe 6 adult cases in which PSC was diagnosed many years after well-established AIH. Six patients are described in whom AIH definitely was diagnosed at presentation. No evidence of biliary disease was noted on the initial liver biopsy or endoscopic retrograde cholangiography (ERCP). All patients responded well to immunosuppressive therapy. After an average duration of follow-up of 4.6 years they became resistant to immunosuppression, and developed clear features of PSC, which was confirmed by ERCP in all patients. The average age of the patients at first presentation was 31.3 years, 2 were women and 4 were men, and 3 had ulcerative colitis. We found no specific features at presentation that could predict this evolutionary outcome. In conclusion, patients with well-established AIH can, after variable duration of follow-up, develop PSC. In patients with AIH who become resistant to immunosuppression or develop significant cholestasis, PSC should be ruled out by ERCP.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12447864     DOI: 10.1053/jhep.2002.37200

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  18 in total

1.  Answers to multiple choice questions.

Authors:  Swastik Agrawal; Radha K Dhiman
Journal:  J Clin Exp Hepatol       Date:  2012-12

Review 2.  Clinical Presentation and Outcomes of Autoimmune Hepatitis in Inflammatory Bowel Disease.

Authors:  Ersilia M DeFilippis; Sonal Kumar
Journal:  Dig Dis Sci       Date:  2015-05-22       Impact factor: 3.199

3.  Overlap syndrome of autoimmune hepatitis and primary sclerosing cholangitis complicated with hepatocellular carcinoma.

Authors:  Kazuto Fukuda; Sachiyo Kogita; Yusuke Tsuchimoto; Yoshiyuki Sawai; Takumi Igura; Hideko Ohama; Yuki Makino; Yasushi Matsumoto; Masanori Nakahara; Shin-Ichirou Zushi; Yasuharu Imai
Journal:  Clin J Gastroenterol       Date:  2012-04-07

4.  Clinical significance of immunoglobulin G4-associated autoimmune hepatitis.

Authors:  Takeji Umemura; Yoh Zen; Hideaki Hamano; Satoru Joshita; Tetsuya Ichijo; Kaname Yoshizawa; Kendo Kiyosawa; Masao Ota; Shigeyuki Kawa; Yasuni Nakanuma; Eiji Tanaka
Journal:  J Gastroenterol       Date:  2010-09-23       Impact factor: 7.527

5.  Autoimmune hepatitis: new paradigms in the pathogenesis, diagnosis, and management.

Authors:  Ye H Oo; Stefan G Hubscher; David H Adams
Journal:  Hepatol Int       Date:  2010-05-19       Impact factor: 6.047

6.  Management of patients with difficult autoimmune hepatitis.

Authors:  Richard Parker; Ye Htun Oo; David H Adams
Journal:  Therap Adv Gastroenterol       Date:  2012-11       Impact factor: 4.409

Review 7.  Diagnosis and management of the overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Can J Gastroenterol       Date:  2013-07       Impact factor: 3.522

Review 8.  The overlap syndromes of autoimmune hepatitis.

Authors:  Albert J Czaja
Journal:  Dig Dis Sci       Date:  2012-08-24       Impact factor: 3.199

Review 9.  Overlap syndromes among autoimmune liver diseases.

Authors:  Christian Rust; Ulrich Beuers
Journal:  World J Gastroenterol       Date:  2008-06-07       Impact factor: 5.742

10.  Blockade of BAFF Reshapes the Hepatic B Cell Receptor Repertoire and Attenuates Autoantibody Production in Cholestatic Liver Disease.

Authors:  Manoj Thapa; Dana Tedesco; Sanjeev Gumber; Elizabeth J Elrod; Jin-Hwan Han; William H Kitchens; Joseph F Magliocca; Andrew B Adams; Arash Grakoui
Journal:  J Immunol       Date:  2020-04-24       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.